Interstitial Lung Disease News and Research

RSS

Interstitial lung disease (ILD) is a broad group of lung diseases comprising of more than a hundred distinct disorders. All of these involve scarring or inflammation of the interstitial lung tissue and affect the volume of oxygen that can reach the bloodstream via the respiratory system.

Using high-resolution CT-scans to screen for LAM is cost-effective in non-smoking women

Researchers at the University of Cincinnati have found that using high-resolution CT-scans to screen for lymphangioleiomyomatosis, or LAM, is cost-effective in non-smoking women between 25 and 54 who come to the emergency room for the first time with a collapsed lung.

4 Mar 2010

Researchers receive grant to study how ILD appears in patients with autoimmune diseases

Researchers at the University of Cincinnati Interstitial Lung Disease Center have received a grant from the National Heart, Lung and Blood Institute to study ways ILD first appears in certain patient groups with autoimmune diseases and how to more efficiently diagnose and treat it.

24 Feb 2010

Genetists identify gene signature expressed in skin associated with the occurrence of lung disease

At its most benign, the autoimmune disease scleroderma can discolor parts of the skin of its sufferers. At its most pernicious, it can thicken and harden their skin, their blood vessels, and their internal organs before, in many cases, killing them.

30 Oct 2009

Chronic pediatric cough linked to reflux and allergies

New research shows that chronic cough in children is most often caused by gastroesophageal reflux and allergies. Researchers from Tulane University in New Orleans, LA, evaluated 40 patients aged 5 to 12 years with chronic cough (> 8 weeks in duration) with no obvious cause. Each patient underwent extensive multispecialty testing. Results showed that reflux was the single most commonly associated factor of chronic cough by itself (27.5 percent), followed by allergy (22.5 percent).

8 Sep 2009

Discovery of protein that helps determine progression of idiopathic pulmonary fibrosis

Researchers say the protein - Serum surfactant protein A - is superior to other IPF predictors and could lead to better decisions about treatment and timing of lung transplantation.

4 Jun 2009

Research aims to reduce scarring from heart attacks

A heart damaged by heart attack is usually broken, at least partially, for good.

14 Dec 2008

Biomarkers identified for idiopathic pulmonary fibrosis

The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science.

28 Apr 2008

Methamphetamine use and pulmonary arterial hypertension

The Pulmonary Hypertension Association (PHA), in conjunction with leading pulmonary hypertension specialists, has announced the launch of an educational campaign to raise awareness of the association between pulmonary arterial hypertension (PAH) and stimulant use, particularly methamphetamine use.

24 Mar 2008

Rare lung disease cells indicate higher death risk

Large numbers of certain cells in the lungs of patients diagnosed with idiopathic pulmonary fibrosis may increase their chance of death, University of Cincinnati (UC) researchers have discovered.

17 Jan 2008

Smoking belies milder disease but worse prognosis for idiopathic pulmonary fibrosis patients

Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London.

16 Jan 2008

New classification system for rare lung diseases in infants

A new classification system of rare lung diseases in infants is improving diagnosis and treatment.

3 Dec 2007

Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease typically characterized by the slow but progressive onset of shortness of breath or cough.

1 Jun 2007

New form of idiopathic pulmonary fibrosis found

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disorder from which most patients die within 5 years after diagnosis.

30 May 2007

Lessons from our patients: development of a warm autopsy program

Thanks in large part to a dying patient's generosity, researchers have for the first time begun to analyze the progression of idiopathic pulmonary fibrosis (IPF), a degenerative illness distinguished by lung inflammation, scarring and diminished breathing capacity that typically leads to death within about five years of diagnosis.

7 Jun 2006

University of Nottingham academic awarded prestigious professorship for research into lung disease

An academic at The University of Nottingham has been awarded a unique professorship by a leading national charity in recognition of his research, which aims to improve the medical care of patients with lung disease and respiratory infections.

30 Nov 2005

Millennium Pharmaceuticals discovers protein biomarkers that could play a role in the early detection of rheumatoid arthritis

Researchers at Millennium Pharmaceuticals today announced the discovery of a panel of protein biomarkers that could play a role in the early detection, prognosis and monitoring of rheumatoid arthritis (RA).

14 Dec 2004

New advances in sickle cell disease

Excruciating pain episodes, recurrent pneumonias, strokes, severe infections, chronic hemolytic anemia, and secondary pulmonary hypertension are common complications of sickle cell disease, a life-threatening inherited defect in blood that causes normally disc-shaped red blood cells to take on a sickle shape.

6 Dec 2004

FDA approves Tarceva (erlotinib)

OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

20 Nov 2004